CAR-T cell therapy
4 stories related to this topic, newest first.
ncbi.nlm.nih.govRecent Developments in CAR-T Therapy for Autoimmunity and GSK's Discontinuation of Leucovorin
Researchers are exploring CAR-T cell therapy's potential in treating autoimmune diseases beyond cancer. GlaxoSmithKline announced it will discontinue leucovorin, a drug used in chemotherapy support. These updates highlight ongoing advancements and changes in the biotechnology sec…
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)Woman with Three Autoimmune Diseases Achieves Remission After CAR-T Cell Therapy in Germany
A 47-year-old woman with severe autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid antibody syndrome received CAR-T cell therapy at University Hospital Erlangen in Germany last year. The treatment, which targets CD19 on B-cells, led to remission within wee…
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)CAR-T Therapy Shows Increasing Remissions in Autoimmune Diseases with Rising Experimentation and Investment
CAR-T cell therapy, originally developed for cancer treatment, is achieving more remissions in patients with autoimmune diseases. According to STAT News, this progress has prompted additional clinical trials and investments from pharmaceutical companies.
Substrate placeholder — needs review · Wikimedia Commons (CC BY-SA 3.0)Researchers Report CAR-T Cell Therapy Success in Severe Autoimmune Disease Case
A 47-year-old woman with three severe autoimmune diseases received experimental CAR-T cell therapy in early 2025 after nine failed treatments. The therapy, originally developed for cancer, targets problematic immune cells to induce remission. The patient has since returned to nor…